SDS Number 110533 Approved/Revised 11-Aug-2006 Version 7
AMERGE TABLETS
Material
SAFETY DATA SHEET
1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE
COMPANY/UNDERTAKING
Material AMERGE TABLETS
AMERGE TABLETS 1.0 MG * AMERGE TABLETS 2.5 MG * NARAGRAN
Synonyms
TABLETS 2.5 MG * NARAMIG TABLETS 2.5 MG * NDC NO 0173-0561-00 *
NDC NO 0173-0562-00 * NARATRIPTAN HYDROCHLORIDE, FORMULATED
PRODUCT
GlaxoSmithKline, Corporate Environment, Health & Safety
Company Name
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information: +44-20-8047-5000
Transport Emergency (EU) +44-1865-407333
Medical Emergency +1-612-221-3999, Ext 221
Information and Advice: US number, available 24 hours
Multi-language response
GlaxoSmithKline, Corporate Environment, Health & Safety
One Franklin Plaza, 200 N 16th Street
Philadelphia, PA 19102-1225 US
US General Information: +1-888-825-5249
Transport Emergency (non EU) +1-703-527-3887
US number, available 24 hours
Multi-language response
2. COMPOSITION / INFORMATION ON INGREDIENTS
Percentage
Ingredients CAS RN
NARATRIPTAN HYDROCHLORIDE 0.3 to 0.8
143388-64-1
NON-HAZARDOUS INGREDIENTS 99.2 to 99.7
Unassigned
3. HAZARDS IDENTIFICATION
Expected to be non-combustible.
Fire and Explosion
Health Handling this product in its final form presents minimal risk from
occupational exposure.
Health effects information is based on hazards of components.
Environment No information is available about the potential of this product to produce
adverse environmental effects.
4. FIRST-AID MEASURES
Page 1 / 6
SDS Number 110533 Approved/Revised 11-Aug-2006 Version 7
AMERGE TABLETS
Material
Ingestion Never attempt to induce vomiting. Do not attempt to give any solid or liquid
by mouth if the exposed subject is unconscious or semi-conscious. Wash
out the mouth with water. If the exposed subject is fully conscious, give
plenty of water to drink. Obtain medical attention.
Inhalation Physical form suggests that risk of inhalation exposure is negligible.
Skin Contact Using appropriate personal protective equipment, remove contaminated
clothing and flush exposed area with large amounts of water. Obtain
medical attention if skin reaction occurs, which may be immediate or
delayed.
Eye Contact Wash immediately with clean and gently flowing water. Continue for at least
15 minutes. Obtain medical attention.
NOTES TO HEALTH PROFESSIONALS
Medical Treatment Treat according to locally accepted protocols. For additional guidance, refer
to the current prescribing information or to the local poison control
information centre.
Medical Conditions Refer to prescribing information for detailed description of medical
conditions caused by or aggravated by overexposure to this product.
Caused or Aggravated
by Exposure
Health Surveillance Pre-placement and periodic health surveillance is not usually indicated. The
final determination of the need for health surveillance should be determined
Procedures
by local risk assessment.
Antidotes No specific antidotes are recommended.
5. FIRE-FIGHTING MEASURES
Fire and Explosion Not expected for the product, although the packaging is combustible.
Hazards
Extinguishing Media Water, dry powder or foam extinguishers are recommended. Carbon
dioxide extinguishers may be ineffective.
Special Firefighting For single units (packages): No special requirements needed. For larger
amounts (multiple packages/pallets) of product: Since toxic, corrosive or
Procedures
flammable vapours might be evolved from fires involving this product and
associated packaging, self contained breathing apparatus and full protective
equipment are recommended for firefighters. If possible, contain and collect
firefighting water for later disposal.
Hazardous Combustion Toxic, corrosive or flammable thermal decomposition products are
expected when the product is exposed to fire.
Products
6. ACCIDENTAL RELEASE MEASURES
Personal Precautions Wear protective clothing and equipment consistent with the degree of
hazard.
Environmental Precautions For large spills, take precautions to prevent entry into waterways, sewers, or
surface drainage systems.
Clean-up Methods Collect and place it in a suitable, properly labelled container for recovery or
disposal.
Decontamination No specific decontamination or detoxification procedures have been
identified for this product.
Procedures
7. HANDLING AND STORAGE
HANDLING
General Requirements Avoid breaking or crushing tablets.
Page 2 / 6
SDS Number 110533 Approved/Revised 11-Aug-2006 Version 7
AMERGE TABLETS
Material
STORAGE No storage requirements necessary for occupational hazards. Follow
product information storage instructions to maintain efficacy.
8. EXPOSURE CONTROLS/PERSONAL PROTECTION
NARATRIPTAN HYDROCHLORIDE
INGREDIENT
3
GSK Occupational
Hazard Category
GSK Occupational 50 mcg/m3 (15 MIN STEL)
Exposure Limit 25 mcg/m3 (8 HR TWA)
Other Equipment or None required for normal handling. Wash hands and arms thoroughly after
handling.
Procedures
9. PHYSICAL AND CHEMICAL PROPERTIES
Appearance
White.
Colour
Tablet.
Physical Form
10. STABILITY AND REACTIVITY
Stability This product is expected to be stable.
Conditions to Avoid None for normal handling of this product.
11. TOXICOLOGICAL INFORMATION
Oral Toxicity Not expected to be toxic following ingestion.
Skin Effects Irritation is not expected following direct contact.
Eye Effects Irritation is not expected following direct contact with eyes.
Target Organ Effects Adverse effects might occur in the following organ(s) following
overexposure: cardiovascular system.
Sensitisation Sensitisation (allergic skin reaction) is not expected.
Genetic Toxicity Not expected to be genotoxic under occupational exposure conditions.
Carcinogenicity No components are listed as carcinogens by GSK, IARC, NTP or US
OSHA.
Reproductive Effects Not expected to produce adverse effects on fertility or development under
occupational exposure conditions.
Pharmacological Effects This product contains active ingredient(s) with the following activity: a
5-hydroxytryptamine agonist. It is an agent intended for the treatment of
migraine. Adverse effects of overexposure might include: symptoms of
hypersensitivity (such as skin rash, hives, itching, and difficulty breathing);
increased blood pressure; vomiting; nausea; tingling.
Other Adverse Effects None known for occupational exposure.
12. ECOLOGICAL INFORMATION
Summary This material contains an active pharmaceutical ingredient that has been
tested, and no environmental effects have been identified. Local regulations
and procedures should be consulted prior to environmental release.
Specific information on the active pharmaceutical ingredient is provided
below.
ECOTOXICITY
Aquatic
Page 3 / 6
SDS Number 110533 Approved/Revised 11-Aug-2006 Version 7
AMERGE TABLETS
Material
Activated Sludge This material contains an active pharmaceutical ingredient that is not toxic
to activated sludge microorganisms.
Respiration
IC50: 100 to 1000 mg/l, 3 Hours, Activated sludge
Algal This material contains an active pharmaceutical ingredient that is not toxic
to algae.
IC50: > 100 mg/l, 72 Hours, Scenedesmus subspicatus,
green algae, Static test
NOEL: 100 mg/l, 72 Hours, Scenedesmus subspicatus,
green algae, Static test
* Daphnid This material contains an active pharmaceutical ingredient that is not toxic
to daphnids.
EC50: 300 mg/l, 48 Hours, Daphnia magna, Static test
NOEL: 160 mg/l, 48 Hours, Daphnia magna, Static test
Fish This material contains an active pharmaceutical ingredient that is not toxic
to fish.
Juvenile Oncorhyncus mykiss, rainbow trout
EC50: > 100 mg/l, 96 Hours, Static renewal test
Juvenile Oncorhyncus mykiss, rainbow trout
NOEL: 100 mg/l, 96 Hours, Static renewal test
MOBILITY
Solubility This material contains an active pharmaceutical ingredient that for
environmental fate predictions has solubility in water.
Volatility This material contains an active pharmaceutical ingredient that will not
readily enter into the air from hard surfaces or from a container of the pure
substance. This material contains an active pharmaceutical ingredient that
will not readily enter into air from water.
Henry's Law Constant Estimated at 25 C
Adsorption This material contains an active pharmaceutical ingredient that is likely to
adsorb to soil or sediment. The active pharmaceutical ingredient may
persist in soil or sediment if this mixture is released directly to the
environment.
Soil Sediment Sorption 3.18 to 3.36, Measured
(log Koc):
Partitioning This material contains an active pharmaceutical ingredient with
octanol/water partition coefficient data that suggests that for environmental
fate predictions the active pharmaceutical ingredient will not have the
tendency to distribute into fats.
PERSISTENCE/DEGRADATION
Hydrolysis This material contains an active pharmaceutical ingredient that has been
shown to be chemically stable in water. Hydrolysis is unlikely to be a
significant depletion mechanism.
Half-Life, Neutral: > 1 Years, Calculated
Photolysis This material contains an active pharmaceutical ingredient that is unlikely to
undergo photodegradation.
UV/Visible Spectrum: 282.5 nm
Page 4 / 6
SDS Number 110533 Approved/Revised 11-Aug-2006 Version 7
AMERGE TABLETS
Material
Biodegradation This material contains an active pharmaceutical ingredient that is not
readily biodegradable but is inherently biodegradable (as defined by 1993
OECD Testing Guidelines) and is not expected to persist in the
environment.
Aerobic - Ready
Percent Degradation: < 1 %, 28 days, Modified Sturm test.
Aerobic - Inherent
Percent Degradation: 27 %, 28 days, Modified Zahn-Wellens, primary
biodegradation, loss of parent., Activated sludge
Percent Degradation: 3 %, 28 days, Modified Zahn-Wellens, DOC
removal., Activated sludge
Aerobic - Soil
Percent Degradation: 3 to 36 %, 64 days
13. DISPOSAL CONSIDERATIONS
Disposal Collect for recycling or recovery if possible. The disposal method for
rejected products/returned goods must ensure that they cannot be re-sold or
Recommendations
re-used.
* Regulatory Requirements Observe all local and national regulations when disposing of this product.
14. TRANSPORT INFORMATION
The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only
authorised persons trained and competent in accordance with appropriate national and international
regulatory requirements may prepare dangerous goods for transport.
UN Classification and Labelling
Transportation and shipping of this product is not restricted. It has no known,
Transport Information
significant hazards requiring special packaging or labelling for air, maritime, US
or European ground transport purposes.
15. REGULATORY INFORMATION
The information included below is an overview of the major regulatory requirements. It should not be
considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.
EU Classification and Labelling
Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal
product, cosmetic product or medical device.
US OSHA Standard (29 CFR Part 1910.1200)
Classification This dosage form is exempt from the requirements of the OSHA Hazard
Communication Standard.
Other US Regulations
TSCA Status Exempt
16. OTHER INFORMATION
References GSK Hazard Determination
Date Approved/Revised 11-Aug-2006 SDS Version Number 7
SDS Sections Updated
Sections Subsections
DISPOSAL CONSIDERATIONS Regulatory Requirements
IDENTIFICATION OF SUBSTANCE / PREPARATION AND
OF COMPANY
Page 5 / 6
SDS Number 110533 Approved/Revised 11-Aug-2006 Version 7
AMERGE TABLETS
Material
SDS Sections Updated
Sections Subsections
REGULATORY INFORMATION US Environmental (EPA) Requirements
The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate
as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the
responsibility of the user to determine the applicability of this information and the suitability of the material
or product for any particular purpose.
Page 6 / 6
|